| Company Name: | Lorus Therapeutics, Incorporated | | Ticker Symbol: | LRP | | | WWW Address: | www.lorusthera.com | | CEO: | Dr.Aiping Young | | No. of Employees: | 27 | | Common Issue Type: | CS | | Business Description: | A life sciences company focused on the discovery, research and development of effective anticancer therapies with a high safety profile.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.05 |  0.0 | - | - | 0 | 0.06 | 0.04 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 12.4 | 248.2 | 1.40 | -0.03 | 0.00 | 0.0 | 0.0 | 0.25 - 0.02 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.05 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 12.4 | mil |
| Latest Shares Outstanding | 248.2 | mil |
| Earnings pS (EPS) | -0.03 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 1,593 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 0.0 | mil |
| Float as % of Shares Outstanding | 0.0 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 27,458.80 | % |
| Research & Devlopment (R&D) as % of Revenue | 37,994.10 | % |
| Gross Profit Margin | 94.1 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -50.5 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -61.9 | % |
| Current Ratio | 5.1 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 124.0 | % |
| Working Capital pS | 0.04 | $ |
| Cash pS | 0.03 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -0.01 | $ |
| Cash Flow pS | -0.02 | $ |
| Free Cash Flow pS | -0.04 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -5.00 | |
| Price/Cash Flow | -2.5 | |
| Price/Free Cash Flow | -1.3 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -16.7 | 77 | 664 | 1,306 |
| 4 Weeks | 0.08 | 0.02 | 0.07 | -28.6 | 82 | 867 | 16,465 |
| 13 Weeks | 0.15 | 0.02 | 0.12 | -58.3 | 55 | 421 | 26,516 |
| 26 Weeks | 0.18 | 0.02 | 0.16 | -68.8 | 46 | 365 | 46,034 |
| 52 Weeks | 0.25 | 0.02 | 0.24 | -79.2 | 33 | 307 | 76,805 |
| YTD | 0.21 | 0.02 | - | -72.2 | 43 | 293 | 61,905 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.05 | 0.05 | 0.08 | 0.12 | 0.13 | 1.40 | 1.38 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -16.12 | 5.0 | 75.79 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -49.42 | NA | -53.22 |
| R&D | -19.45 | NA | -19.87 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -100.0 | -100.0 | -57.0 |
| Earnings % | -100.0 | -100.0 | 0.0 |
| EPS % | -100.0 | -100.0 | 0.0 |
| EPS $ | -0.03 | -0.03 | 0.02 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 69.27 |
| Current Ratio | 4.0 |
| Quick Ratio (Acid Test) | 3.5 |
| Liquidity Ratio (Cash) | 3.47 |
| Receivables Turnover | 0.0 |
| Average Collection Period | 0 |
| Working Capital/Equity | -208.7 |
| Working Capital pS | 0.04 |
| Cash-Flow pS | -0.03 |
| Free Cash-Flow pS | -0.05 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -0.96 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 133.2 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 143.3 |
| LT Debt/Total Liabilities | 82.4 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 11.57 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.22 |
| Tobin's Q Ratio | 1.06 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -1.72 |
| Enterprise Value (EV)/Free Cash Flow | -0.29 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -5.00 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -2.5 |
| Price/Free Cash Flow Ratio - LTM | -1.3 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.06 |
| Current Liabilities pS | 0.01 |
| Tangible Book Value pS - LTM | -0.01 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 0.04 |
| Cash pS - LTM | 0.03 |
| Cash Flow pS - LTM | -0.02 |
| Free Cash Flow pS - LTM | -0.04 |
| Earnings pS (EPS) | -0.03 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -23,962.79 |
| Free Cash Flow Margin 5YEAR AVG | -78,452.77 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -0.01 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.00 |
| Return on Capital Invested (ROCI) | -71.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -104.8 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -54.6 |
| Return on Assets (ROA) - 5YEAR AVRG. | -85.3 |
| Gross Profit Margin | 94.1 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 0 |
| Revenue per Employee | 1,593 |
| Net Income per Employee | -235,815 |
| Average Collection Period | 0 |
| Receivables Turnover | 0.0 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 2,158.14 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.01 |
| Fixed Assets Turnover | 0.05 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.02 |
| Revenue per $ Plant | 0.18 |
| Revenue per $ Common Equity | -0.01 |
| Revenue per $ Capital Invested | 0.00 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 10769.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 3679.8 |
| Research & Devlopment (R&D) as % of Revenue | 14230.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 14230.2 |
|
|  
|
| |
 |  |